View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

GSK plc - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: GSK's $2.2 billion Zantac settlement removes uncertainty rela...

The company's credit metrics will remain comfortable for the rating if the settlement payments are funded mainly by debt.

GSK plc - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: Key facts and statistics - LTM June 2024

A summary company profile, detailing GSK plc’s business operations and financial highlights.

GSK plc - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: Delaware court decision to allow Zantac cases to proceed incr...

Our assessment of impact of recent ruling that expert witnesses may testify for plaintiffs in Zantac litigation

GSK plc: Update to credit opinion

Our credit view of this issuer reflects its low leverage and improving credit metrics, constrained by its degree of event risk related to acquisitions.

GSK plc: GSK strengthens pipeline with acquisition of Aiolos Bio, a cr...

The acquisition improves the company's respiratory pipeline in the context of patent cliffs arising later in the decade. Leverage metrics are unaffected

GSK plc - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: Key facts and statistics - LTM June 2023

A summary company profile, detailing GSK’s business operations and financial highlights.

GSK plc: Update to credit opinion

Our credit view of this issuer reflects its low leverage and improving credit metrics, constrained by its degree of event risk related to acquisitions.

GSK plc - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: BELLUS acquisition strengthens GSK's pipeline in specialty me...

BELLUS acquisition strengthens GSK's pipeline in specialty medicines

GSK plc - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: Update following 2022 annual results

Our credit view of this issuer reflects its limited exposure to future patent expiries until the second part of this decade, and solid growth profile.

GSK plc - September 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc - June 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GSK plc: Separation of Haleon is not deleveraging but GSK is on growth...

Our credit view of this issuer reflects its diversified operations across pharmaceuticals and vaccines, against credit metrics which still require some improvement.

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch